|
1
|
Tan M and Yu D: Molecular mechanisms of
erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol.
608:119–129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kavallaris M: Microtubules and resistance
to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pusztai L, Wagner P, Ibrahim N, Rivera E,
Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming
DR, et al: Phase II study of tariquidar, a selective P-glycoprotein
inhibitor, in patients with chemotherapy-resistant, advanced breast
carcinoma. Cancer. 104:682–691. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katsetos CD, Herman MM and Mörk SJ: Class
III beta-tubulin in human development and cancer. Cell Motil
Cytoskeleton. 55:77–96. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee KM, Cao D, Itami A, Pour PM, Hruban
RH, Maitra A and Ouellette MM: Class III beta-tubulin, a marker of
resistance to paclitaxel, is overexpressed in pancreatic ductal
adenocarcinoma and intraepithelial neoplasia. Histopathology.
51:539–546. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sève P and Dumontet C: Is class III
beta-tubulin a predictive factor in patients receiving
tubulin-binding agents? Lancet Oncol. 9:168–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Katsetos CD, Dráberová E, Legido A,
Dumontet C and Dráber P: Tubulin targets in the pathobiology and
therapy of glioblastoma multiforme. I. Class III beta-tubulin. J
Cell Physiol. 221:505–513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kavallaris M, Kuo DY, Burkhart CA, Regl
DL, Norris MD, Haber M and Horwitz SB: Taxol-resistant epithelial
ovarian tumors are associated with altered expression of specific
beta-tubulin isotypes. J Clin Invest. 100:1282–1293. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gan PP, Pasquier E and Kavallaris M: Class
III beta-tubulin mediates sensitivity to chemotherapeutic drugs in
non small cell lung cancer. Cancer Res. 67:9356–9363. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wilhelm M, Schlegl J, Hahne H, Gholami AM,
Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx
H, et al: Mass-spectrometry-based draft of the human proteome.
Nature. 509:582–587. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sá-Correia I and Teixeira MC: 2D
electrophoresis-based expression proteomics: A microbiologist's
perspective. Expert Rev Proteomics. 7:943–953. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Villeneuve DJ, Hembruff SL, Veitch Z,
Cecchetto M, Dew WA and Parissenti AM: cDNA microarray analysis of
isogenic paclitaxel- and doxorubicin-resistant breast tumor cell
lines reveals distinct drug-specific genetic signatures of
resistance. Breast Cancer Res Treat. 96:17–39. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carmichael J, DeGraff WG, Gazdar AF, Minna
JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated
colorimetric assay: Assessment of chemosensitivity testing. Cancer
Res. 47:936–942. 1987.PubMed/NCBI
|
|
14
|
Sakai A, Otani M, Miyamoto A, Yoshida H,
Furuya E and Tanigawa N: Identification of phosphorylated serine-15
and −82 residues of HSPB1 in 5-fluorouracil-resistant colorectal
cancer cells by proteomics. J Proteomics. 75:806–818. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aldridge GM, Podrebarac DM, Greenough WT
and Weiler IJ: The use of total protein stains as loading controls:
an alternative to high-abundance single-protein controls in
semi-quantitative immunoblotting. J Neurosci Methods. 172:250–254.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong HY, Yoo GS and Choi JK: Direct Blue
71 staining of proteins bound to blotting membranes.
Electrophoresis. 21:841–845. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Murphy ME: The HSP70 family and cancer.
Carcinogenesis. 34:1181–1188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan
XY, Lau GK, Beretta L and Fan ST: Association of mortalin (HSPA9)
with liver cancer metastasis and prediction for early tumor
recurrence. Mol Cell Proteomics. 7:315–325. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rozenberg P, Kocsis J, Saar M, Prohászka
Z, Füst G and Fishelson Z: Elevated levels of mitochondrial
mortalin and cytosolic HSP70 in blood as risk factors in patients
with colorectal cancer. Int J Cancer. 133:514–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu Y, Li J and Lee AS: GRP78/BiP inhibits
endoplasmic reticulum BIK and protects human breast cancer cells
against estrogen starvation-induced apoptosis. Cancer Res.
67:3734–3740. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roller C and Maddalo D: The molecular
chaperone GRP78/BiP in the development of chemoresistance:
Mechanism and possible treatment. Front Pharmacol. 4:102013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim JW, Sahm H, You J and Wang M:
Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant
human ovarian cancer cells. Anticancer Res. 30:2577–2581.
2010.PubMed/NCBI
|
|
23
|
Obchoei S, Wongkhan S, Wongkham C, Li M,
Yao Q and Chen C: Cyclophilin A: Potential functions and
therapeutic target for human cancer. Med Sci Monit. 15:RA221–RA232.
2009.PubMed/NCBI
|
|
24
|
Nigro P, Pompilio G and Capogrossi MC:
Cyclophilin A: A key player for human disease. Cell Death Dis.
4:e8882013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J,
Choe W and Kim SS: Overexpressed cyclophilin A in cancer cells
renders resistance to hypoxia- and cisplatin-induced cell death.
Cancer Res. 67:3654–3662. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pandita A, Kumar B, Manvati S, Vaishnavi
S, Singh SK and Bamezai RN: Synergistic combination of gemcitabine
and dietary molecule induces apoptosis in pancreatic cancer cells
and down regulates PKM2 expression. PLoS One. 9:e1071542014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao X, Yang J, Li R, Liu S, Xu Y, Zheng
W, Yi Y, Luo Y, Gong F, Peng H, et al: Deregulation of
mitochondrial ATPsyn-β in acute myeloid leukemia cells and with
increased drug resistance. PLoS One. 8:e836102013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dreyfuss G, Kim VN and Kataoka N:
Messenger-RNA-binding proteins and the messages they carry. Nat Rev
Mol Cell Biol. 3:195–205. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rauch J, O'Neill E, Mack B, Matthias C,
Munz M, Kolch W and Gires O: Heterogeneous nuclear
ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells
by regulating A-Raf transcription. Cancer Res. 70:1679–1688. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liao J, Ku NO and Omary MB: Stress,
apoptosis, and mitosis induce phosphorylation of human keratin 8 at
Ser-73 in tissues and cultured cells. J Biol Chem. 272:17565–17573.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barak V, Goike H, Panaretakis KW and
Einarsson R: Clinical utility of cytokeratins as tumor markers.
Clin Biochem. 37:529–540. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rubin CI and Atweh GF: The role of
stathmin in the regulation of the cell cycle. J Cell Biochem.
93:242–250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alli E, Yang JM, Ford JM and Hait WN:
Reversal of stathmin-mediated resistance to paclitaxel and
vinblastine in human breast carcinoma cells. Mol Pharmacol.
71:1233–1240. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Werner HM, Trovik J, Halle MK, Wik E,
Akslen LA, Birkeland E, Bredholt T, Tangen IL, Krakstad C and
Salvesen HB: Stathmin protein level, a potential predictive marker
for taxane treatment response in endometrial cancer. PLoS One.
9:e901412014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gache V, Louwagie M, Garin J, Caudron N,
Lafanechere L and Valiron O: Identification of proteins binding the
native tubulin dimer. Biochem Biophys Res Commun. 327:35–42. 2005.
View Article : Google Scholar : PubMed/NCBI
|
